H19 imprinted maternally expressed transcript promoter (H19 promoter)

The H19 imprinted maternally expressed transcript promoter is a DNA regulatory element that controls the expression of the H19 long non-coding RNA (lncRNA). In normal physiology, this promoter is highly active during fetal development but is transcriptionally silenced in most adult tissues shortly after birth, with the exception of a few specific cell types. However, the H19 promoter is frequently reactivated or overexpressed in a wide variety of human malignancies, including bladder, lung, and ovarian cancers, where it contributes to tumor progression and metastasis (Source: PubMed, PMID: 17510401). This tumor-specific expression profile makes the H19 promoter an attractive tool for cancer gene therapy. Therapeutic strategies, such as the drug candidate BC-819 (Inodiftagene vaxadenotrep), utilize the H19 promoter to drive the expression of a potent toxin, like Diphtheria Toxin A, specifically within cancer cells while sparing healthy adult tissue (Source: NIH, ClinicalTrials.gov). By hijacking the cancer cell's own transcriptional machinery, this approach achieves high selectivity and reduces systemic toxicity compared to traditional chemotherapy.

Other names

H19 regulatory regionH19 gene promoterH19/IGF2 imprinting control region

Transcriptional targeting; the promoter is used to drive the tumor-specific expression of a cytotoxic gene, such as Diphtheria toxin A (DTA), leading to selective apoptosis of cancer cells.